Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

This randomised, double-blind, parallel-group Phase I/II trial tests intravenous ketamine 0.5 mg/kg given once weekly for four weeks versus placebo in patients with major depressive disorder in the context of advanced cancer and palliative care.

Primary aim is to assess antidepressant efficacy and tolerability as an adjuvant treatment; outcomes include depressive symptom change, safety, and palliative-relevant measures.